



SID

Società Italiana
di Diabetologia



I diversi tipi di disegno sperimentale

Eva Pagano

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

SID Academy: Metodologia degli studi clinici in diabetologia

Bologna, 20-21 marzo 2018

La dr.ssa Eva Pagano dichiara di NON aver
ricevuto negli ultimi due anni compensi o
finanziamenti da Aziende Farmaceutiche e/o
Diagnostiche

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siiditalia@siiditalia.it

Domanda

Siamo tutti d'accordo sulla definizione di disegno sperimentale?

- A) Studio prospettico
- B) Randomized controlled trial
- C) Studio comparativo di una relazione esposizione-effetto
- D) Studio con assegnazione dell'esposizione da parte del ricercatore

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Types of experimental studies – classification schemes

Experimental studies can be classified according to:

- The object of randomization (when present)
- The aspect of interventions being evaluated
- How participants are exposed to interventions
- The number of participants
- Whether investigators and/or participants know which intervention is being studied

Which is the randomisation object?

- ❑ Individually randomized trials
 - Eligible individuals are randomized
 - Self-selection of persons volunteering for enrollment
- ❑ Cluster randomized trials
 - Clusters (e.g., communities, hospitals) or other aggregates of people (e.g., workplace) are randomized, and all (consenting) persons enrolled

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Cluster trial: PROs

- ❑ Reduce the threat of “contamination”
- ❑ Randomization by group may be the only feasible method of conducting a trial (intervention naturally applied at a cluster level)
- ❑ Enhance subject compliance
- ❑ Increase administrative efficiency

Cluster RCT may have different design (parallel, factorial, ecc.)

Cluster trial: CONs

- ❑ Commonly, prior consent to randomization by individual cluster participant is not feasible
- ❑ Blinding of a cluster RCT is difficult
- ❑ The conclusion may relate to clusters, to individual participant or both
- ❑ Reduced statistical efficiency (due to intra-cluster correlation)

Diapositiva preparata da EVA PAGGI NO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes

Journal of Diabetes Science and Technology
2016, Vol. 10(3) 772–781
© 2015 Diabetes Technology Society
Reprints and permissions:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1932296815617487
dst.sagepub.com


Bernhard Kulzer, PhD¹, Wilfried Daenschel, MD², Ingrid Daenschel, MD³,
Erhard G. Siegel, MD⁴, Wendelin Schramm, MD⁵, Christopher G. Parkin, MS⁶,
Diethelm Messinger, MSc⁷, Joerg Weissmann, MD⁸, Zdenka Djuric, MD⁸,
Angelika Mueller, PhD⁸, Iris Vesper, MS⁸, and Lutz Heinemann, PhD⁹

- To determine if use of integrated PDM in daily life improve glycemic control in insulin-treated type 2 diabetes patients:
PDM versus usual care

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

- 12-months, cluster-randomized, multicentre clinical trials at two different levels of ambulatory care:
 1. General practitioners (PDM-ProValue GP study)
 2. Diabetes specialists (PDM-ProValue DSP study)
- Study outcome: change in HbA1c from baseline to 12 months

“Although randomization of patients within a clinic or practice site is the most commonly used study design, this “within site” approach has the potential to impact investigator behaviors as they become knowledgeable and experienced in both the experimental and the control treatment protocols. This creates a strong potential for “cross-contamination” of study participants (patients and clinicians), which may reduce any potential differences seen between the study groups”

Stepped wedge trials

- Pragmatic study design used for the evaluation of service delivery or policy interventions
- In an initial period no clusters are exposed. Subsequently, at regular interval (**steps**) one/some clusters are randomized to cross from the control to the intervention. At the end all the clusters are exposed.

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Stepped wedge trials

Cluster	Period 1	Period 2	Period 3	Period 4	Period 5
1					
2					
3					
4					

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Stepped wedge trials: PROs and CONs

- Allows to adopt a randomized design in situations where randomization to either control or intervention is not suitable
- but
- In case of small cluster size or low intra-cluster correlation can be inefficient
- Data analysis needs to be adjusted for the confounding effect of calendar time

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Improving Access to Thrombolysis and Inhospital Management Times in Ischemic Stroke

A Stepped-Wedge Randomized Trial

Julie Haesebaert, MD, PhD; Norbert Nighoghossian, MD, PhD; Catherine Mercey, PhD; Anne Termoz, MSc; Sylvie Porthault, MD; Laurent Derex, MD, PhD; Pierre-Yves Gueugniaud, MD, PhD; Estelle Bravant, MSc; Michel Rahmoud, MD, PhD; Anne-Marie Schott, MD, PhD; on behalf of the AVC II trial group*

Background and Purpose—A suboptimal number of ischemic stroke patients eligible for thrombolysis actually receive it, partly because of extended in-hospital delays. We developed a comprehensive program designed for emergency unit staff and evaluated its effectiveness for reducing in-hospital times and improving access to thrombolysis.

Methods—We conducted a randomized stepped-wedge controlled trial in 18 emergency units. The sequentially implemented training intervention, targeting emergency physicians and nurses, was based on specifically designed videos and interactive simulation workshops on in-hospital management optimization. The effectiveness was assessed on in-hospital times and thrombolysis proportion. During the study period, all consecutive patients with confirmed ischemic stroke and no contraindications to thrombolysis were included.

Each EU was considered as a **cluster** (ie, 18 clusters). The 18 EUs were arranged into **4 groups** based on their geographical proximity. Each group, thus, composed of 4 to 5 EUs. The trial was performed in **4 steps**, and each group of clusters was randomly assigned to one step (steps 1–4).




Figure 1. Study design and clusters randomization according to the different time periods.

Which aspect of the interventions is being evaluated?

- Efficacy vs effectiveness trials
- Superiority vs equivalence trials/ non inferiority
- Phase I, II, III trials

Diapositiva preparata da EVA PAGANO e ceduta alla Societa Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Efficacy vs. effectiveness

□ Efficacy: does the intervention work in the people who actually receive it?

- These trials tend to be **explanatory**
- Goal here is high compliance

□ Effectiveness: how does the intervention work in people to whom it has been offered

- Tend to be **pragmatic**
- For intervention with proven efficacy offered to heterogeneous group of patient

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Superiority vs. equivalence/ non inferiority trials

□ Superiority trials:

- Intended to determine if new treatment is different from (better than) placebo or existing treatment (active control)

□ Equivalence trials:

- Intended to determine if a new treatment is therapeutically similar to a reference treatment (margin of equivalence)


□ Non-inferiority trials:

- Intended to determine that new treatment is not worse than a reference treatment by more than an acceptable amount (margin of non-inferiority)

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Reasons for equivalence / non inferiority trials

2 Comparison of superiority, equivalence and non-inferiority* hypotheses based on a 2% margin of difference in event rates



- Existing effective treatment
- Placebo-controlled trial unethical
 - Life-threatening illness
- New treatment not substantially better than existing treatment
 - May have fewer side effects, greater convenience, lower cost, higher quality of life, or provide an alternative or second line therapy

Noninferiority and equivalence: CONS

- ❑ Difficult to specify an appropriate non-inferiority margin
- ❑ Large sample size required compared to superiority trials
- ❑ A well executed trial cannot be distinguished, on the basis of outcome data alone, from a poorly executed trial that fails to find a true difference (ie. poor compliance, poor diagnostic criteria, bias endpoint assessment)

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

ORIGIN

STUDY PROTOCOL

Open Access



CrossMark

Alogliptin after Acute Coronary Events in Patients with Type 2 Diabetes

William B. White, M.D., Christopher E. Bressan, M.D., Steven E. Nissen, M.D., Richard J. Heizer, M.D., Alfonso T. Perez, M.D., Peter W. Jones, M.D., and the Alogliptin Study Group

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John P. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna Garg, M.S., Robert Josse, M.B., B.S., Keith D. Kaufman, M.D., Joerg Koglin, M.D., Scott Korn, M.D., John M. Lachin, Sc.D., Darren K. McGuire, M.D., M.H.Sc., Michael J. Pencina, Ph.D., Eberhard Standl, M.D., Ph.D., Peter P. Stein, M.D., Shailaja Suryawanshi, Ph.D., Frans Van de Werf, M.D., Ph.D., Eric D. Peterson, M.D., M.P.H., and Rury R. Holman, M.B., Ch.B., for the TECOS Study Group*

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial

Shinichi Oyama⁴, Masataka Sata⁵, Isao Taguchi⁶, Junya Ako¹⁰, Yasushi Sakata¹¹, Toshihisa Anzai¹², Kira Yamashina⁹, Yoshihiko Saito¹⁶, Yasunori Sato¹⁷, and the CANDLE Trial Investigators*

Key Messages

Matthew R. Weir, M.D., M.P.H., James E. Davidson, M.D., Frederick A. Heizer, M.D., Ph.D., Michael J. Heizer, Ph.D., Michael J. Heizer, M.D., M.P.H., Darren K. McGuire, M.D., and Itamar Raz, M.D., and Investigators*

Diapositiva preparata da EVA PAGANO e ceduta alla Societa Italiana di Diabetologia. Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Phase I, II, III, IV trials

Phase I

- Initial safety and tolerability
- Determine safe dosage range
- Identify side effects
- On healthy subjects

10-50

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Phase I, II, III, IV trials

Phase I

Phase II

- Initial safety and tolerability
- Determine safe dosage range
- Identify side effects
- On healthy subjects

10-50

- Efficacy
- Dose response
- Further evaluation of safety

50-150

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it


Phase I, II, III, IV trials



• Initial safety and tolerability • Determine safe dosage range • Identify side effects • On healthy subjects	• Efficacy • Dose response • Further evaluation of safety	• Effectiveness • Compare to commonly used therapies • Monitor side effects
10-50	50-150	300-1000

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Phase I, II, III, IV trials




How the participants are exposed to the intervention?

- Parallel trials
- Crossover trials
- Factorial design

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Parallel design




■ **FIGURE 10.1**

In a randomized trial, the investigator (a) selects a sample from the population, (b) measures baseline variables, (c) randomizes the participants, (d) applies interventions (one should be a blinded placebo, if possible), (e) follows up the cohort, (f) measures outcome variables (blindly, if possible) and analyzes the results.

Crossover trial: design

- Each patient is given more than one treatment, each at different times in the study, with the intent of estimating differences between them
- The simplest trial is the two-treatment (A and B), two-period design. Patients are randomized to receive either A followed by B or B followed by A
- Washout period between treatment periods

Crossover design



■ **FIGURE 11.4**

In the cross-over randomized trial, the investigator (a) selects a sample from the population, (b) measures baseline variables, (c) randomizes the participants, (d) applies interventions, (e) measures outcome variables, (f) allows washout period to reduce carryover effect, (g) applies intervention to former placebo group, (h) measures outcome variables again.

Crossover trial: when to use it

- ❑ In chronic, incurable disease (to keep same patients in all the study periods)
- ❑ The condition must be stable (to avoid “period effects”)
- ❑ The effects of interventions should have rapid onset and short duration (to avoid “carry-over effect”)

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Crossover trial: PROs

- ❑ In respect to prognostic factors, the treatment groups are identical, simply because the same individuals receive both treatments
- ❑ Increased compliance and recruitment
- ❑ Increased efficiency then parallel designs
 - Lower variability (within-subject)
 - Lower sample size

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Crossover trial: CONs

- ❑ Possibility of «carryover» effect
- ❑ Increased likelihood of dropouts (longer time and possible side effects)
- ❑ The underlying disease must have a constant intensity during all treatments periods

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections

The GOLD Randomized Clinical Trial

Marcus Lind, MD, PhD; William Polonsky, PhD; Irl B. Hirsch, MD; Tim Heise, MD; Jan Bolinder, MD, PhD; Sofia Dahlqvist; Erik Schwarz, MD, PhD; Arndís Finna Ólafsdóttir, RN; Anders Frid, MD, PhD; Hans Wedel, PhD; Elsa Ahlén, MD; Thomas Nyström, MD, PhD; Jarl Hellman, MD

IMPORTANCE The majority of individuals with type 1 diabetes do not meet recommended glycemic targets.

OBJECTIVE To evaluate the effects of continuous glucose monitoring in adults with type 1 diabetes treated with multiple daily insulin injections.

DESIGN, SETTING, AND PARTICIPANTS Open-label crossover randomized clinical trial conducted in 15 diabetes outpatient clinics in Sweden between February 24, 2014, and June 1, 2016 that included 161 individuals with type 1 diabetes and hemoglobin A_{1c} (HbA_{1c}) of at least 7.5% (58 mmol/mol) treated with multiple daily insulin injections.

INTERVENTIONS Participants were randomized to receive treatment using a continuous glucose monitoring system or conventional treatment for 26 weeks, separated by a washout period of 17 weeks.

- ← Editorial page 363
- ← Related article page 371
- + Supplemental content

- To evaluate the effects of continuous glucose monitoring in adults with type 1 diabetes treated with multiple daily injections:
 - CGM versus conventional therapy using only self-monitoring of blood glucose
- Open-label crossover randomized clinical trial in Sweden (15 diabetes outpatient clinics)
- Outcome measures: difference in HbA1c between weeks 26 and 69 for the two treatments, hypoglycaemia, well-being, and glycemic variability

Figure 1. Screening, Randomization, and Analysis for Continuous Glucose Monitoring and Conventional Treatment Groups





Figure 2. HbA_{1c} Values at Inclusion, Randomization, and During the 2 Different Periods of Treatment



Hemoglobin A1c (HbA_{1c}) was measured according to the National Glycohemoglobin Standardization Program (NGSP). Data markers and error bars indicate mean (95% CIs). Data were plotted using the last-observation-carried-forward approach.

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
 Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Domanda

Researchers evaluated the effectiveness of the cannabinoid dronabinol on central neuropathic pain in patients with multiple sclerosis. A randomised double blind placebo controlled crossover trial study design was used. Each treatment period was for three weeks, separated by a three week washout period.


Which of the following statements, if any, are true?

- a) All participants received both treatments in the same sequence order
- b) Each participant acted as his or her own control
- c) The purpose of the washout period was to allow the effects of the first treatment to dissipate before starting the second treatment
- d) The crossover study design required more participants than if a “between subjects” study design had been used to compare dronabinol and placebo

Factorial design: definition

- ❑ Two or more treatments are evaluated not only separately, but also in combination and against a control
- ❑ Each **level** of one independent variable (**factor**) is combined with each level of the others to produce all possible combinations
- ❑ The simplest case is a 2×2 design, a study involving two treatment factors, each with two levels
- ❑ Data collected for all possible combination of the X levels of the N factors of interest

Factorial design



■ **FIGURE 11.2**

In a factorial randomized trial, the investigator (a) selects a sample from the population; (b) measures baseline variables; (c) randomly assigns two active interventions and their controls to four groups, as shown; (d) applies interventions; (e) follows up the cohorts; (f) measures outcome variables.

Domanda

Researchers explored the effectiveness of three interventions in preventing falls among older people. The three interventions were group based exercise, home hazard management, and vision improvement.

A randomised controlled trial with a full factorial design was used. The control treatment was no intervention. The study design allowed the effectiveness of each intervention to be evaluated plus exploration of their effects when combined. The main outcome measure was self reported time to first fall after randomisation. The researchers reported that group based exercise was the most effective single intervention in reducing the number of falls.

How many treatment groups were there in the above randomized controlled trial that incorporated a full factorial design?

- a) Four
- b) Six
- c) Seven
- d) Eight

Factorial design: when to use it

- ❑ To be interested in learning about treatment combinations
 - Examining the **interaction** between treatments
- ❑ To examine the dose-response characteristics of the simultaneous use of treatments

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Main effect

Average change in the response associated with a change in the **level** of the factor: **marginal totals**
(Design 3X2)

		Factor A			
		A_1	A_2	A_3	
Factor B	B_1	Cell A_1B_1 Scores on the dependent variable	Cell A_2B_1 Scores on the dependent variable	Cell A_3B_1 Scores on the dependent variable	$\bar{X}_{B_1}$
	B_2	Cell A_1B_2 Scores on the dependent variable	Cell A_2B_2 Scores on the dependent variable	Cell A_3B_2 Scores on the dependent variable	$\bar{X}_{B_2}$
		$\bar{X}_{A_1}$	$\bar{X}_{A_2}$	$\bar{X}_{A_3}$	

Interaction effect

- ❑ An interaction is between **factors** (not levels)
- ❑ When differences on one factor depend on the level you are on another factor (e.g. treatment or placebo)
- ❑ You know there's an interaction if you can't talk about effect on one factor without mentioning the other factor
- ❑ Designing a study 'to specifically' test for interaction require a much larger sample size, and therefore it is essential that the trial is powered to detect an interaction effect

Factorial design: PROs

- ❑ In the absence of interaction, allows great efficiency in estimating main effects (same precision as two single-factor trials using twice the sample size)
- ❑ In the presence of interaction, is the only type of design that permits study of treatment interaction
- ❑ Treatments acting through different mechanism are more appropriate for factorial design

Factorial design: CONs

- ❑ Treatments must be administered without changing dosage in the presence of each other (ie cumulative side effect)
- ❑ There must be acceptable not to administer the individual treatments (no treatment or placebo group) or administer them at a lower dose
- ❑ Potential for adverse effects due to “poly-pharmacy”

Diapositiva preparata da EYA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial^{1–3}

Giovanni Annuzzi, Lutgarda Bozzetto, Giuseppina Costabile, Rosalba Giacco, Anna Mangione, Gaia Anzilli, Marilena Vitale, Claudia Vetrani, Paola Cipriano, Giuseppina Della Corte, Fabrizio Passaia, Gabriele Riccardi, and Angela A Rivellese

Diabetologia (2015) 58:1551–1560
DOI 10.1007/s00125-015-3597-2

ARTICLE

Polyphenol-rich diets improve glucose metabolism in people at high cardiometabolic risk: a controlled randomised intervention trial

Lutgarda Bozzetto¹ • Giovanni Annuzzi¹ • Giovanni Pacini² • Giuseppina Costabile¹ •
Claudia Vetrani¹ • Marilena Vitale¹ • Ettore Griffo¹ • Angela Giacco¹ •
Claudia De Natale¹ • Sara Coccozza¹ • Giuseppe Della Pepa¹ • Andrea Tura² •
Gabriele Riccardi¹ • Angela A. Rivellese¹

- To elucidate in individuals at high risk of type 2 diabetes and CVD, the medium-term effects of diets naturally rich in different sources of polyphenols and/or marine LCn3s
- Outcome measures: 8 weeks triglyceride concentrations and oxidative distress
- A 2X2 factorial design comparing:
 1. Control diet, low in LCn3 and polyphenols
 2. High LCn3 diet, rich in LCn3 and low in polyphenols;
 3. High polyphenol diet, low in LCn3 and rich in polyphenols;
 4. High LCn3 and high polyphenol diet, rich in LCn3 and polyphenols.

TABLE 4

Absolute changes after the intervention (8 wk minus baseline) in postprandial incremental AUCs of plasma and lipoprotein triglycerides, cholesterol, and apo B-48¹

	Control (n = 20)	High LCn3s (n = 19)	High polyphenols (n = 20)	High polyphenols and high LCn3s (n = 19)	LCn3 effect	Polyphenol effect	Polyphenol- LCn3 interaction
Plasma triglyceride (mg/dL · 6 h)	52 ± 294	-69 ± 275	-41 ± 236	-40 ± 149	0.310	0.526	0.252
Plasma total cholesterol (mg/dL · 6 h)	-16 ± 42	-2 ± 72	14 ± 58	-10 ± 52	0.816	0.476	0.187
Chylomicron triglycerides (mg/dL · 6 h)	54 ± 173	53 ± 210	71 ± 194	1.7 ± 74	0.189	0.939	0.174
Chylomicron cholesterol (mg/dL · 6 h)	1.4 ± 6.8	2.4 ± 7.5*	1.8 ± 5.7	-0.4 ± 2.8	0.351	0.742	0.047
Large VLDL triglycerides (mg/dL · 6 h)	16 ± 138	-3.8 ± 160	9.8 ± 136	-42 ± 63	0.169	0.384	0.342
Large VLDL cholesterol (mg/dL · 6 h)	1.0 ± 2.3	-0.1 ± 2.1	0.1 ± 2.1	-5.8 ± 14	0.297	0.676	0.825
Large VLDL apo B-48 (μg/mL · 6 h)	1.1 ± 12	0.27 ± 9.83	0.29 ± 7.86	0.12 ± 4.80	0.741	0.750	0.802

¹ All values are means ± SDs. *Significantly different from the control group, $P < 0.05$ (ANOVA and least-significant-difference post hoc test). apo B-48, apolipoprotein B-48; LCn3, long-chain n-3 PUFA.

² Two-factor ANOVA of absolute values at 8 wk adjusted for baseline values as covariate. $P < 0.05$ indicates a significant difference.

How many participants are included?

- From N-of-1 trials to mega trials


- Fixed size

- Sequential trials

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

N-of-1 trial or individual patient trial

- These can be thought of as a form of crossover trial
- Each participant receives the experimental arm for a period of time and then the control/comparison arm during a different period of time
- There can be many such periods of time in these studies
 - XCCCXXCCXX
- The participant does not know which intervention is occurring during each period



Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials

M. J. Yelland¹, C. J. Nikles², N. McNairn³, C. B. Del Mar⁴, P. J. Schluter⁵ and R. M. Brown⁶

- To assess the effectiveness for the short term choice of drugs for osteoarthritis
- Sustained release paracetamol versus celecoxib
- 2 weeks of each treatment, for 3 treatment cycles
- Outcome measures: pain, stiffness and functional limitation scores
- 41 patients completing the n-of-1 trial
- Patient receives each treatment, with treatment order decided at random
- A crossover trial in a single patient; enable decision on the single patient

Mega trials

- ❑ These studies are meant to be HUGE but to collect only a limited amount of data (to make them affordable and practical)
- ❑ Are usually multi-center, from different countries
- ❑ Have the aim to obtain 'increased statistical power' and to achieve wider generalizability and can pick up small effects

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

METHODOLOGY

Open Access



Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events in Diabetes (ASCEND)

Theingi Aung², Richard Haynes¹, Jill Barton¹, Jolyon Cox¹, Aleksandra Murawski¹, Kevin Mughny¹, Michael Lay¹, Jane Armitage¹, Louise Bowman^{1*} and ASCEND Study Collaborative Group

ASCEND (A Study of Cardiovascular Events in Diabetes) is a 2 × 2 factorial design randomised study to assess whether aspirin 100 mg daily versus placebo and separately, omega-3 fatty acids 1 g daily versus placebo, reduce the risk of cardiovascular events in individuals with diabetes who do not already have diagnosed occlusive arterial disease, and whether any such benefits outweigh any hazards from bleeding. To minimise costs

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

□ To identify people with diabetes:

1. Centrally held diabetes registers
2. General practice diabetes registers

“Information on approximately 600,000 people listed on 58 centrally held diabetes registers was obtained, and 300,188 potentially eligible patients were invited to join the study. In addition, 785 GP practices mailed invitations to 120,875 patients. A further 2,340 potential study participants were identified via other routes. In total, 423,403 people with diabetes were invited to take part; 26,462 entered the 2-month, pre-randomisation, run-in phase; and 15,480 were randomised.”

Diapositiva preparata da IDA PAO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Fixed size trial

- ❑ The investigator establish deductively the number of participants (sample size) that they will include
- ❑ Statistical methods used to calculate sample size maximize the chance of detecting a statistically and clinically significant difference between the interventions when a difference really exist

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Sequential trial

- ❑ Contrast is with the more traditional fixed size trial in which the number of participants is determined based on a priori sample size calculations
- ❑ Has a parallel design
- ❑ Number of participants is NOT specified before the trial begins
- ❑ Participants are recruited until the question is answered (or it becomes clear that there is no possibility to detect a difference between the arms)

Interim analysis

- Analysis comparing intervention groups at any time before the formal completion of the trial, usually before recruitment is complete.
- Often used with "stopping rules" so that a trial can be stopped if participants are being put at risk unnecessarily.
- Timing and frequency of interim analyses should be specified in the protocol.

Sequential trial: PROs and CONs

□ Stopping for **efficacy**:

- Patients benefit sooner from the new treatment
- Less information on secondary outcomes (including safety) and subgroups

□ Stopping for **futility**:

- Efficient with respect of costs, time, effort,
- Reduces expected sample size
- Helps protection of participants against unnecessary exposure to potentially harmful treatment
- May not be able to determine if the treatment is merely ineffective or actually harmful

Diapositiva preparata da EVA SAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Who knows which intervention is being assessed?

- ❑ Open trials
- ❑ Single-blind trials
- ❑ Double-blind trials
- ❑ Triple and quadruple-blind trials
- ❑ Blinding. Relevant groups who may/may not have knowledge of treatment assignments
 - Participants, investigators/clinicians administering intervention, investigators assessing outcomes, data analyst(s)

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

❑ Open trials

- All participants and investigators know who is getting which intervention

❑ Single-blind

- The participants (usually) or the investigators assessing outcome (alternately) do not have knowledge of the treatment assignments

❑ Double-blind

- Two groups do not know—usually it is the participants and the outcome assessors/investigators

❑ Triple or quadruple blinding

- Three or four of the relevant groups (prior slide) are not aware of the treatment assignment

Innovative designs: Adaptive design

- Allows adaptations or modifications to trial design after its initiation without undermining validity and integrity of trial
- Requires the trial to be conducted in several stages with access to the accumulated data (real-time data)
- At any stage, the data may be analyzed and next stages redesigned taking into account all available data

Adaptive design: institutional definitions

□ **EMA:** “An adaptive design clinical study is defined as a study design if statistical methodology allows the modification of a design element (e.g. sample size, randomisation ratio, number of treatment arms) at an interim analysis with full control of the type I error”

□ **FDA:** “An adaptive design clinical study is defined as a study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study

Adaptive design: PROs and CONs

- May improve trial efficiency for the sponsor and the participants in the trial

But

- Can pose operational challenges because of their complexity, and the process of adapting a trial can introduce bias

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Typea of adaptive design trials

Adaptive randomization design

Group sequential design

Sample size re-estimation design

Drop-the-loser design

Adaptive dose-finding design

Biomarker-adaptive design

Adaptive treatment-switching design

Hypothesis-adaptive design

Adaptive seamless phase II/III design

A multiple-adaptive design

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it



Centro di Riferimento per l'Epidemiologia
e la Prevenzione Oncologica in Piemonte

www.cpo.it

Eva Pagano

eva.pagano@cpo.it

Diapositiva preparata da EVA PAGANO e ceduta alla Società Italiana di Diabetologia.
Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it

Grazie per l'attenzione!